Keiryth Barreto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Keiryth Barreto has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ana Ruiz
Universidad del Zulia
1 shared publication - Carem Francelys Prieto Fuenmayor
Universidad Católica de Cuenca
1 shared publication - Fabricio Byron Guerrero Ortiz
Universidad Católica de Cuenca
1 shared publication - Gino Curiel
Universidad del Zulia
1 shared publication - Hermel Medardo Espinosa Espinosa
Universidad Católica de Cuenca
1 shared publication - Jesús Quintero
Instituto de Investigaciones Clínicas “Dr. Américo Negrette”, Facultad de Medicina, Universidad del Zulia, Maracaibo, Venezuela
1 shared publication
Latest Publications
- Open Access
- 6 June 2022
- Published by Universidad Estatal de Milagro (UNEMI) in FACSALUD-UNEMI
- Vol. 6 (10) , 58-68
Factores de crecimiento en plasma rico en plaquetas de individuos sanos tratados con agentes antiplaquetarios
Properties of platelet rich plasma (PRP) were attributed specially of high levels of growth factors (GFs), action of antiplatelet agents could alter the release of GFs from PRP. This study assessed the level of platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF) from PRP of 20 healthy participants before and after treatment with antiplatelet agents. Venous blood samples were collected from the 20 participants to obtain PPP and PRP by the single centrifugation method of Anitua. The same 20 participants were divided in two groups: 10 received a dairy oral dose of Aspirin (100 mg) and 10 of Clopidogrel (75 mg) for 7 days. The procedure to obtain PPP and PRP was repeated after treatment. Levels of GFs were measured using the technique of ELISA. When pretreatment and posttreatment levels were compared, a significant decrease was found in the group treated with Aspirin in the PDGF-BB (PPP: <0,05) and EGF (PPP: <0,05/ PRP: <0,04) and group treated with Clopidogrel in PDGF-BB (PPP: <0,009/ PRP:<0,0001), VEGF-A (PPP: <0,001/ PRP<0,01) and EGF (PPP: <0,04/ PRP<0,018). Decreases in GFs after treatment of each antiplatelets agent, specially Clopidogrel, cannot ensure that clinical effect of platelet GFs would be completely affected, future clinical studies are needed.
- 6 June 2022
- Published by Universidad Estatal de Milagro (UNEMI) in FACSALUD-UNEMI
- Vol. 6 (10) , 58-68
Open AccessFactores de crecimiento en plasma rico en plaquetas de individuos sanos tratados con agentes antiplaquetarios
Properties of platelet rich plasma (PRP) were attributed specially of high levels of growth factors (GFs), action of antiplatelet agents could alter the release of GFs from PRP. This study assessed the level of platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF) from PRP of 20 healthy participants before and after treatment with antiplatelet agents. Venous blood samples were collected from the 20 participants to obtain PPP and PRP by the single centrifugation method of Anitua. The same 20 participants were divided in two groups: 10 received a dairy oral dose of Aspirin (100 mg) and 10 of Clopidogrel (75 mg) for 7 days. The procedure to obtain PPP and PRP was repeated after treatment. Levels of GFs were measured using the technique of ELISA. When pretreatment and posttreatment levels were compared, a significant decrease was found in the group treated with Aspirin in the PDGF-BB (PPP: <0,05) and EGF (PPP: <0,05/ PRP: <0,04) and group treated with Clopidogrel in PDGF-BB (PPP: <0,009/ PRP:<0,0001), VEGF-A (PPP: <0,001/ PRP<0,01) and EGF (PPP: <0,04/ PRP<0,018). Decreases in GFs after treatment of each antiplatelets agent, specially Clopidogrel, cannot ensure that clinical effect of platelet GFs would be completely affected, future clinical studies are needed.